TTK Healthcare share price today

TTK Healthcare Ltd's share price was ₹915.65 at the close on 6 November 2026. It has been rising for 10 weeks. That is 9.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹768 and ₹1,158, and at that close it sat 38% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today TTK Healthcare Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Over the last 11 years the share price moved +1% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), highest quarterly profit in 16 quarters and number of shareholders up 49% in a year.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹233 crore, +14.2% on a year earlier.

2. Highest quarterly profit in 16 quarters

   Profit of ₹223 crore in the September 2026 quarter is the highest of the last 16 quarters.

3. Number of shareholders up 49% in a year

   23,993 shareholders in the September 2026 quarter, against 16,134 a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), TTK Healthcare reported revenue of ₹233 crore, up 14.2% from ₹204 crore a year earlier, and a profit of ₹223 crore, up 1,015.0% from ₹20.0 crore.

TTK Healthcare results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

TTK Healthcare closed at ₹915.65 on 6 November 2026, down 20.6% from ₹1,153.30 a year earlier (7 November 2025) and up 31.7% over five years. Its highest weekly close since March 2016 was ₹1,739.80 on 13 September 2024.

TTK Healthcare share price: then and now

Weekly closing prices. Each change is the move from that price to the 6 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

562 weekly closes from 11 March 2016 to 6 November 2026.

6 Nov 2026: TTK Healthcare closed at ₹915.65, up 1.1% on the week and down 10.4% on the month. Results for July to September 2026: Revenue up 14.2% and profit up 1,015.0% on a year earlier.

Earlier

• 17 Jul 2026: ex-date for a dividend of ₹10 a share.

TTK Healthcare paid ₹10 a share in regular dividends in the 12 months to 7 November 2026 (1 payment), a yield of 1.09% at the ₹915.65 close on 6 November 2026. The last was a dividend of ₹10 a share, ex-date 17 July 2026.

TTK Healthcare dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. TTK Healthcare Ltd paid out 22% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 7 November 2026.

TTK Healthcare is on one of our India lists: Pharma stocks.

TTK Healthcare Ltd earned ₹223 Cr of net profit in the Sep 2026 quarter, +1,015.0% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹66.0 Cr. Over 10 years profit has grown 11.1% a year on average. That is 95.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹20.0 Cr.

For the full year, FY26 profit was ₹66.0 Cr (−19.5% on the year before).

Why profit moved: revenue changed +14.2% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +269.7% and revenue +11.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

TTK Healthcare Ltd reported ₹233 Cr of revenue in the Sep 2026 quarter, +14.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 5.1% a year on average. The last full year, FY26, came in at ₹857 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹918 Cr.

FY26 revenue was ₹857 Cr, +7.0% on the year before.

Recent pace: the last four quarters grew +11.3% on average, against 5.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +11.3%, against +9.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +319.7%, against +86.1% a year (accelerating).

TTK Healthcare Ltd's operating margin was 1.6% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 3.0% and 8.0%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed −0.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years TTK Healthcare Ltd's operations used more cash than they brought in, so cash conversion was −14%, a gap worth watching. In FY26 its operations used ₹21.0 Cr of cash, against ₹66.0 Cr of profit. After ₹2.0 Cr of spending on assets, free cash was −₹23.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −14% of profit came in as cash: the cash cycle got 65 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 65 days longer. The next section looks at where the cash is stuck.

TTK Healthcare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 63 days in FY26, up from −2 days in FY21. It spent ₹30.0 Cr on assets over the last 3 years. Customers take 47 days to pay, and stock sits for 98 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹857 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹148 Cr is tied up in the business at any time.

FY26: customers took 47 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 63 days, longer than FY21's −2.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 47 days after that. Suppliers are paid at 83 days. Together that makes the 63-day cycle.

Spending on assets: ₹30.0 Cr over the last 3 years, against ₹30.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

TTK Healthcare Ltd's P/E is 17.9×, near the low end of its own history: it has been lower only 3% of the time. Its usual P/E (the middle reading) is 32.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.